GlassScriptPhysician profile
Chienwei T Chen
NPI 1992795256
$7,520.52
in general payments reported to CMS, 2019-2025
23 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $152 · 2022: $965 · 2023: $1,807 · 2024: $2,005 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,969.12 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $1,094.19 | 2023-2025 | Qulipta, Botox, Ubrelvy |
| Novo Nordisk INC | $806.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $767.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $534.11 | 2019-2025 | Otezla, Repatha, Enbrel |
| Lilly USA, LLC | $494.85 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $340.99 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $306.02 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $227.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $186.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.16 | 2023-2025 | Jardiance |
| Sanofi Pasteur INC. | $125.02 | 2019-2025 | |
| Pfizer INC. | $106.66 | 2020-2025 | |
| Dexcom, INC. | $100.66 | 2023-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $86.08 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $42.03 | 2024 | Rystiggo |
| Bausch Health US, LLC | $26.45 | 2023 | Aplenzin |
| Avadel Cns Pharmaceuticals, LLC | $24.65 | 2025 | Lumryz |
| Lucid Diagnostics INC. | $24.46 | 2022 | |
| Gilead Sciences, INC. | $22.63 | 2019 | |
| Hologic Sales and Service, LLC | $22.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2023 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chienwei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.